3 March 2026 - BEAM ALLIANCEBEAM is turning 10!What a journey since the association was founded in 2016! Since then, awareness of the looming AMR problem has grown,…
11 December 2025 - BEAM ALLIANCEEU Reaches Landmark Agreement on Pharmaceutical Legislation RevisionAfter a long night of negotiations, EU co-legislators have reached a long-awaited political agreement on the revision of the Union’s…
20 October 2025 - BEAM ALLIANCEDefining Eligibility for ‘Priority Antimicrobials’: A Critical Step for Effective PULL IncentivesThe General Pharmaceutical Legislation (GPL) should provide broad guidelines for eligibility, leaving the EMA to refine the details. The GPL…
20 October 2025 - BEAM ALLIANCETransferable Priority Review Vouchers (TPRVs): Lessons from the US, Implications for EUIf a choice must be made, TEEV offer a clearer, more reliable incentive for SMEs, making them a more appealing…
20 October 2025 - BEAM ALLIANCEThe Future of the TEE Voucher in EU Pharmaceutical LegislationThe TEE Voucher is widely supported by SMEs, industry, and investors. Though not perfect, its predictability makes it attractive to…
20 October 2025 - BEAM ALLIANCEHow Can a Subscription Model Help Incentivizing Antimicrobial Innovation in the EU?An EU-funded revenue guarantee (ensuring predictability and reducing reliance on voluntary participation) could be highly effective, provided the incentives are…
12 March 2026 - BioVersysBioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary TuberculosisThe compound represents a novel concept to overcome resistance and potentiate the activity of an existing antibiotic, ethionamide (Eto) or…
10 March 2026 - Centauri TherapeuticsCentauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infectionsThe recognition of the potential value of our technology further underpins our belief in its potential to transform treatment paradigms…
4 March 2026 - BioVersysBioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and ChemotherapyWe are now advancing BV100 into global registrational study program with our two trials RIV-TARGET and RIV-CARE.
25 February 2026 - Basilea Pharmaceutica InternationalBasilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamWe are very pleased to receive the continued funding from BARDA to support the further development of our novel antibiotic…
24 February 2026 - Centauri TherapeuticsCentauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidateThe funding from AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to investing in urgently needed antimicrobial…
19 February 2026 - BioVersysBioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of MedicineThe bEto-TB trial demonstrates the power of sustained investment in global health research. The development of AlpE reflects not only…
25 June 2026Therapeutics and Antimicrobial Resistance (AMR)The meeting aims to strengthen cross-disciplinary connections, highlight opportunities for impact, and catalyse new initiatives in therapeutics research, outreach and…
17 April 2026ESCMID Global 2026ESCMID Global is the world’s premier meeting in the fields of Clinical Microbiology and Infectious Diseases.
26 March 2026REVIVE Webinar: Journal Club: Key findings from recent publications in antimicrobial R&DIn this webinar, individuals who have co-authored publications that have had particular impact in the field of antimicrobial R&D will…
13 March 2026REVIVE Webinar: Current developments in Clostridioides difficile prevention, therapy and R&DREVIVE webinar being done in collaboration with the Peggy Lillis Foundation
3 March 202610th AMR ConferenceSave the date! The 10th AMR Conference will be organized as a face-to-face event on 3-4 March 2026, in Basel.…
19 February 2026REVIVE Webinar: Innovating for Impact: Tackling Chronic Lung Infections in Cystic Fibrosis through New AntimicrobialsREVIVE webinar in collaboration with CF AMR Syndicate.